Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Sobi's Emapalumab-Lzsg Gets FDA Fast Track Status

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    27/05/2024 07:50
    May 27(Reuters) - Swedish Orphan Biovitrum AB (Publ)
 SOBIV.ST :
    * SAID ON FRIDAY SOBI RECEIVES US FDA FAST TRACK DESIGNATION
FOR
EMAPALUMAB-LZSG BEING INVESTIGATED IN MACROPHAGE ACTIVATION
SYNDROME

  
 Source text for Workspace:  urn:newsml:reuters.com:*:nGNX2NyYH3
 Further company coverage:  SOBIV.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news